USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN

Infantile hemangiomas (IHs) are the most common tumors detectable in infants, including 5–10% of the neonates. Despite the spontaneous involution characteristic of the uncomplicated course of the disease, IHs require therapy in order to prevent disfigurement, functional disorders and cankering. Effe...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. I. Kucherov, Yu. V. Zhirkova, M. G. Rekhviashvili, I. A. Mikhalev, L. N. Moskvitina, D. L. Shiporev
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2014-07-01
Series:Педиатрическая фармакология
Subjects:
Online Access:https://www.pedpharma.ru/jour/article/view/72
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849685675532615680
author Yu. I. Kucherov
Yu. V. Zhirkova
M. G. Rekhviashvili
I. A. Mikhalev
L. N. Moskvitina
D. L. Shiporev
author_facet Yu. I. Kucherov
Yu. V. Zhirkova
M. G. Rekhviashvili
I. A. Mikhalev
L. N. Moskvitina
D. L. Shiporev
author_sort Yu. I. Kucherov
collection DOAJ
description Infantile hemangiomas (IHs) are the most common tumors detectable in infants, including 5–10% of the neonates. Despite the spontaneous involution characteristic of the uncomplicated course of the disease, IHs require therapy in order to prevent disfigurement, functional disorders and cankering. Effective experience of treating IHs with non-selective-blocker propranol was described in 2008. More than 200 articles on effectiveness and safety of -blockers for IH treatment and assessment of potential side effects have been published since then. The article presents published data on the assessment of effectiveness of treating difficult to access hemangiomas with propranol on the basis of the applicable standards of medical care rendering. Special attention is given to the side effects induced by administration of this drug. According to the results of the published scientific works, -blockers appear to be rather effective for IH treatment and feature a high safety profile. However, it is necessary to continue clinical research and establish a sufficient evidence basis in order to definitively confirm this hypothesis.
format Article
id doaj-art-dec18c24daa04f328d49f2b9e98e5f41
institution DOAJ
issn 1727-5776
2500-3089
language Russian
publishDate 2014-07-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-dec18c24daa04f328d49f2b9e98e5f412025-08-20T03:23:02ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892014-07-01114465010.15690/pf.v11i4.106372USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDRENYu. I. Kucherov0Yu. V. Zhirkova1M. G. Rekhviashvili2I. A. Mikhalev3L. N. Moskvitina4D. L. Shiporev5Scientific Center of Children’s Health, Moscow, Russian Federation Pirogov Russian National Medical Research University, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian Federation Pirogov Russian National Medical Research University, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationInfantile hemangiomas (IHs) are the most common tumors detectable in infants, including 5–10% of the neonates. Despite the spontaneous involution characteristic of the uncomplicated course of the disease, IHs require therapy in order to prevent disfigurement, functional disorders and cankering. Effective experience of treating IHs with non-selective-blocker propranol was described in 2008. More than 200 articles on effectiveness and safety of -blockers for IH treatment and assessment of potential side effects have been published since then. The article presents published data on the assessment of effectiveness of treating difficult to access hemangiomas with propranol on the basis of the applicable standards of medical care rendering. Special attention is given to the side effects induced by administration of this drug. According to the results of the published scientific works, -blockers appear to be rather effective for IH treatment and feature a high safety profile. However, it is necessary to continue clinical research and establish a sufficient evidence basis in order to definitively confirm this hypothesis.https://www.pedpharma.ru/jour/article/view/72hemangiomaclassificationtreatmentpropranoleffectivenesssafetyside effectsneonates
spellingShingle Yu. I. Kucherov
Yu. V. Zhirkova
M. G. Rekhviashvili
I. A. Mikhalev
L. N. Moskvitina
D. L. Shiporev
USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN
Педиатрическая фармакология
hemangioma
classification
treatment
propranol
effectiveness
safety
side effects
neonates
title USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN
title_full USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN
title_fullStr USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN
title_full_unstemmed USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN
title_short USE OF PROPRANOL FOR TREATING COMPLICATED HEMANGIOMAS IN CHILDREN
title_sort use of propranol for treating complicated hemangiomas in children
topic hemangioma
classification
treatment
propranol
effectiveness
safety
side effects
neonates
url https://www.pedpharma.ru/jour/article/view/72
work_keys_str_mv AT yuikucherov useofpropranolfortreatingcomplicatedhemangiomasinchildren
AT yuvzhirkova useofpropranolfortreatingcomplicatedhemangiomasinchildren
AT mgrekhviashvili useofpropranolfortreatingcomplicatedhemangiomasinchildren
AT iamikhalev useofpropranolfortreatingcomplicatedhemangiomasinchildren
AT lnmoskvitina useofpropranolfortreatingcomplicatedhemangiomasinchildren
AT dlshiporev useofpropranolfortreatingcomplicatedhemangiomasinchildren